Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma
Fosun Pharma-Teva collaboration agreement established with goal of accelerating clinical data generation for TEV-56278
Partnership leverages strategic relationships to enable research and development of innovative treatments to advance Teva's Pivot to Growth strategy
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.